ResearcherUniversity of MichiganActive in the last 2 years
Yibin Xu
Matched on ORCID iD 0000-0002-8261-3286; OpenAlex author ID A5054947471. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper
Papers 5
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.4c03159↗
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.2c01769↗
- First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acsptsci.3c00069↗
- Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. First author DOI 10.1021/acs.jmedchem.1c01934↗
- Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells. Co-author DOI 10.1002/cmdc.202000494↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nouri Neamati · 5 shared papers, 2020–2025 · strength 0.95
- Paper Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.4c03159↗
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreati… DOI 10.1021/acs.jmedchem.2c01769↗
- Joyeeta Roy · 4 shared papers, 2022–2025 · strength 0.84
- Paper Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.4c03159↗
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreati… DOI 10.1021/acs.jmedchem.2c01769↗
- Duxin Sun · 3 shared papers, 2022–2025 · strength 0.64
- Paper Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.4c03159↗
- Paper Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreati… DOI 10.1021/acs.jmedchem.2c01769↗
- Paper Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01934↗
- Ding Xue · 2 shared papers, 2022–2023 · strength 0.38
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01934↗
- Mats E. Ljungman · 2 shared papers, 2020–2023 · strength 0.31
- Wen‐Ming Chen · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.